Deal Library / Pharma BD Deal Intelligence

Women's Health Deals

The Pharma Closeout tracks 8 deals, $19.3B in disclosed deal value, 4 with a post-close Outcome Score for Women's Health.

Median Critic Score: 86  ·  Median Outcome Score: 58

Best outcome: Sumitovant Biopharma / Myovant Sciences (60)  ·  Weakest outcome: Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA (16)

All 8 deals

• Sumitovant Biopharma / Myovant Sciences — 2022 · $1.7B · Largely worked — most objectives met.
• Astellas Pharma Inc. / Ogeda SA — 2017 · $850M · Mixed — partial payoff, real shortfalls.
• Mylan Inc. / Famy Care Limited (women's healthcare businesses) — 2015 · $800M · Mixed — partial payoff, real shortfalls.
• Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA — 2013 · $305M · Did not work — the deal failed to deliver.
• Sun Pharmaceutical Industries Limited / Organon & Co. — 2026 · $11.8B
• Organon & Co. / Forendo Pharma — 2021 · $954M
• Perrigo Company Plc / HRA Pharma — 2021 · $2.1B
• Bayer AG / KaNDy Therapeutics Ltd. — 2019 · $875M

← Deal Library  ·  Interactive search  ·  How we score deals